Adults who have B-cell chronic lymphocytic leukemia may receive Fludara® (fludarabine phosphate), a chemotherapy medication that is reserved for use when the cancer has progressed or not responded after other chemotherapy treatment. It is given as a daily injection into a vein (intravenously, or by IV) for 5 days in a row, every 28 days.
Ben Venue Laboratories for Genzyme Corporation manufactures brand-name Fludara. There are also generic versions of Fludara currently available, which are made by various manufacturers.
The active ingredient in Fludara, fludarabine phosphate, was previously available in tablet form. This medicine was called Oforta™. However, the manufacturer discontinued Oforta due to a lack of demand for the medication, and it is no longer available.
(Click Fludara for more details on this chemotherapy medication. This full-length article describes how the drug works, why it may not be suitable for some people, and more.)
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Fludarabine. Drug Facts and Comparisons. Drug Facts and Comparisons 4.0 [online]. 2012. Available from Wolters Kluwer Health, Inc. Accessed October 20, 2012.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed October 20, 2012.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click